0.8134

6.40% +0.0489

After Hours: .82 0.0066 +0.81%

Gritstone Bio Inc (GRTS)

Overview News Price History Option Chain Discussions Forecast

Gritstone Bio Inc stock is currently priced at $0.8134, with a 24-hour trading volume of 1.10M. It has seen a +6.40% increased in the last 24 hours and a -68.59% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.7758 pivot point. If it approaches the $0.8328 resistance level, significant changes may occur.

Previous Close:

$0.7645

Open:

$0.7583

24h Volume:

1.10M

Market Cap:

$86.54M

Revenue:

$1.33M

Net Income/Loss:

$-138.49M

P/E Ratio:

-0.6456

EPS:

-1.26

Net Cash Flow:

$-126.22M

1W Performance:

+10.43%

1M Performance:

-68.59%

6M Performance:

-58.29%

1Y Performance:

-65.82%

1D Range:

$0.7583

$0.8356

52W Range:

$0.6716

$3.33

Gritstone Bio Inc Stock (GRTS) Company Profile

Name

Gritstone Bio Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

510-871-6100

Address

5858 Horton Street, Suite 210, Emeryville, CA

Employee

102

Twitter

@gritstoneonc

Next Earnings Date

2024-05-09

Latest SEC Filings

GRTS's Discussions on Twitter

Gritstone Bio Inc Stock (GRTS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-31-23	Initiated	Evercore ISI	Outperform
Mar-28-23	Initiated	B. Riley Securities	Buy
Oct-31-22	Initiated	Piper Sandler	Overweight
Aug-22-22	Downgrade	Goldman	Neutral → Sell
Dec-15-21	Resumed	Goldman	Neutral
Oct-15-21	Resumed	BTIG Research	Buy
Jan-20-21	Downgrade	Robert W. Baird	Outperform → Underperform
Jul-26-19	Initiated	Robert W. Baird	Outperform
Mar-15-19	Initiated	Raymond James	Outperform
Mar-07-19	Initiated	H.C. Wainwright	Buy
Oct-23-18	Initiated	BTIG Research	Buy
Oct-23-18	Initiated	Goldman	Neutral

View All

Gritstone Bio Inc Stock (GRTS) Latest News

Down -63.39% in 4 Weeks, Here's Why Gritstone bio (GRTS) Looks Ripe for a Turnaround

Zacks Investment Research

Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Crude Oil Surges Over 1%; US Factory Orders Increase In February

Benzinga

Gritstone Bio Inc Stock (GRTS) Financials Data

Gritstone Bio Inc (GRTS) Revenue 2024

GRTS reported a revenue (TTM) of $1.33 million for the quarter ending December 31, 2023, a -85.63% decline year-over-year.

Gritstone Bio Inc (GRTS) Net Income 2024

GRTS net income (TTM) was -$138.49 million for the quarter ending December 31, 2023, a -15.71% decrease year-over-year.

Gritstone Bio Inc (GRTS) Cash Flow 2024

GRTS recorded a free cash flow (TTM) of -$126.22 million for the quarter ending December 31, 2023, a -3.61% decrease year-over-year.

Gritstone Bio Inc (GRTS) Earnings per Share 2024

GRTS earnings per share (TTM) was -$1.20 for the quarter ending December 31, 2023, a +9.77% growth year-over-year.

Gritstone Oncology Inc. is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.